Recently, PharmExec ranked the top 50 pharmaceutical companies in the world according to the sales volume of prescription drugs. SHANGHAI PHARMA ranked 48th on the list for its outstanding performance.
PharmExec has been releasing this list for 21 years since 2000 and has strong credibility. After Chinese pharmaceutical enterprise first ranked in the list last year, there are four Chinese pharmaceutical enterprises on the list this year, namely Yunnan Baiyao, Sino Biopharmaceutical, Hengrui Pharmaceutical and SHANGHAI PHARMA, which shows China’s strength in the global pharmaceutical industry.
In recent years, SHANGHAI PHARMA has developed with the continuous promotion of innovation, developed intensively, internationally and with the combining finance and industry, and it has increased its research and development investment year by year, continuously enhanced its marketing capability, accelerated its international business development, achieved rapid growth in business performance, and continuously improved its industry status. In 2019, the sales revenue of SHANGHAI PHARMA reached 186.566 billion yuan, with a year-on-year increase of 17.27%. Among them, the revenue of pharmaceutical industry was 23.49 billion yuan, with a year-on-year increase of 20.70%, and the growth rate exceeded 20% for 11 consecutive quarters.
The market in Liaoning region is the focus and foothold of SHANGHAI PHARMA Group’s industrial and commercial strategic layout in the north China. As a holding subsidiary of Shanghai Pharmaceutical Holdings Subsidiary,Liaoning Pharmaceutical Foreign Trade Corporation will continue to contribute to the group’s provincial platform construction in Liaoning Province, further deepen the system reform, innovate the development mode, building a solid platform that can serve both the group and the society. Guided by the strategies of the group, it will make more steady contributions to promote the high-quality development of the group.